Credit Suisse Ag Magenta Therapeutics, Inc. Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.62 - $0.79 $27,404 - $34,918	-44,200 Reduced 22.84%	149,300 $113,000
Q3 2022 Nov 10, 2022	SELL	$1.26 - $2.09 $20 - $33	-16 Reduced 0.01%	193,500 $273,000
Q2 2022 Aug 12, 2022	SELL	$0.97 - $3.08 $750 - $2,383	-774 Reduced 0.4%	193,516 $232,000
Q1 2022 May 16, 2022	SELL	$2.55 - $5.23 $331 - $679	-130 Reduced 0.07%	194,290 $563,000
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $168,539 - $316,914	38,045 Added 24.33%	194,420 $861,000
Q3 2021 Nov 12, 2021	BUY	$6.07 - $9.89 $695,348 - $1.13 Million	114,555 Added 273.92%	156,375 $1.14 Million
Q2 2021 Aug 16, 2021	SELL	$9.76 - $14.15 $12,639 - $18,324	-1,295 Reduced 3.0%	41,820 $409,000
Q1 2021 May 14, 2021	SELL	$7.66 - $13.38 $114,317 - $199,683	-14,924 Reduced 25.71%	43,115 $510,000
Q4 2020 Feb 12, 2021	BUY	$6.1 - $7.94 $18,696 - $24,336	3,065 Added 5.58%	58,039 $455,000
Q3 2020 Nov 13, 2020	BUY	$6.52 - $8.94 $226,165 - $310,110	34,688 Added 170.99%	54,974 $374,000
Q2 2020 Aug 12, 2020	BUY	$6.18 - $10.76 $13,837 - $24,091	2,239 Added 12.41%	20,286 $152,000
Q1 2020 May 13, 2020	BUY	$6.03 - $15.24 $108,823 - $275,036	18,047 New	18,047 $113,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.